These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11251642)

  • 1. Type IV phosphodiesterase inhibitor suppresses insulin-dependent myocardial glucose uptake.
    Imahashi K; Yoshioka J; Yamakita T; Yamano S; Kusuoka H; Nishimura T
    Clin Exp Pharmacol Physiol; 2001 Apr; 28(4):290-1. PubMed ID: 11251642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
    Shafiee-Nick R; Pyne NJ; Furman BL
    Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat.
    Carceles MD; Aleixandre F; Fuente T; López-Vidal J; Laorden ML
    Eur J Anaesthesiol; 2003 Mar; 20(3):205-11. PubMed ID: 12650491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
    Eckly AE; Lugnier C
    Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type IV.
    Chini CC; Chini EN; Williams JM; Matousovic K; Dousa TP
    Kidney Int; 1994 Jul; 46(1):28-36. PubMed ID: 7933846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function.
    Miller AH; Vogt GJ; Pearce BD
    Neuropsychopharmacology; 2002 Dec; 27(6):939-48. PubMed ID: 12464451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
    Makhay MM; Houslay MD; O'Donnell JM
    Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochemical distribution of cyclic AMP-dependent 3',5'-nucleotide phosphodiesterase in the rat myocardium.
    Okruhlicová L; Tribulová N; Eckly A; Lugnier C; Slezák J
    Histochem J; 1996 Mar; 28(3):165-72. PubMed ID: 8735283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
    Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
    Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats.
    Yao W; Tian XY; Chen J; Setterberg RB; Lundy MW; Chmielzwski P; Froman CA; Jee WS
    J Musculoskelet Neuronal Interact; 2007; 7(2):119-30. PubMed ID: 17627081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of a phosphodiesterase III in the lysis-sensitive target-induced elevation of cyclic AMP (cAMP) in human natural killer cells.
    Whalen MM; Crews JD
    Biochem Pharmacol; 2000 Aug; 60(4):499-506. PubMed ID: 10874124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
    Sato T; Otaka M; Odashima M; Kato S; Jin M; Konishi N; Matsuhashi T; Watanabe S
    Biochem Biophys Res Commun; 2006 Jul; 346(1):339-44. PubMed ID: 16759642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
    Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
    Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus.
    Suvarna NU; O'Donnell JM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):249-56. PubMed ID: 12065724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase-mediated reinforcement of hippocampal early long-term depression by the type IV-specific phosphodiesterase inhibitor rolipram and its effect on synaptic tagging.
    Navakkode S; Sajikumar S; Frey JU
    J Neurosci; 2005 Nov; 25(46):10664-70. PubMed ID: 16291939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of low-KM cAMP phosphodiesterase in rat nephron segments.
    Yoshida I; Takeda S; Homma S; Kusano E; Asano Y
    Kidney Blood Press Res; 1997; 20(5):307-11. PubMed ID: 9419046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type IV phosphodiesterase activity specifically regulates cAMP-stimulated casein secretion in the rat mammary gland.
    Pooley L
    Biochim Biophys Acta; 2002 Jun; 1590(1-3):84-92. PubMed ID: 12063171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
    Yamaki K; Li X; Hossain MA; Alam AH; Taneda S; Yanagisawa R; Takano H; Yoshino S
    Immunol Invest; 2007; 36(2):131-45. PubMed ID: 17365015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.